[
  {
    "ts": null,
    "headline": "Barclays Downgrades Dexcom (DXCM) to Underweight Citing Intensifying Competition in Core Segments",
    "summary": "DexCom Inc. (NASDAQ:DXCM) is one of the best US stocks to buy and hold in 2026. On January 12, Barclays downgraded DexCom to Underweight from Equal Weight with a price target of $71, which was brought down from $80. The firm anticipated that intensifying competition within Dexcom’s primary insulin-intensive segments throughout 2026 and 2027 would […]",
    "url": "https://finnhub.io/api/news?id=d049625ccd4ff2ebf3b0731c128c997b5a1f954a7639a275a466bfa19224b527",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769521120,
      "headline": "Barclays Downgrades Dexcom (DXCM) to Underweight Citing Intensifying Competition in Core Segments",
      "id": 138270301,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "DexCom Inc. (NASDAQ:DXCM) is one of the best US stocks to buy and hold in 2026. On January 12, Barclays downgraded DexCom to Underweight from Equal Weight with a price target of $71, which was brought down from $80. The firm anticipated that intensifying competition within Dexcom’s primary insulin-intensive segments throughout 2026 and 2027 would […]",
      "url": "https://finnhub.io/api/news?id=d049625ccd4ff2ebf3b0731c128c997b5a1f954a7639a275a466bfa19224b527"
    }
  },
  {
    "ts": null,
    "headline": "Dexcom Schedules Fourth Quarter and Fiscal Year 2025 Earnings Release and Conference Call for February 12, 2026 at 4:30 p.m. Eastern Time.",
    "summary": "SAN DIEGO, January 27, 2026--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2025 financial results after market close on Thursday, February 12, 2026. Management will hold a conference call to review the company's fourth quarter and fiscal year 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations webs",
    "url": "https://finnhub.io/api/news?id=b6963f885beb59a16c2bdc793d1a8d1e59eef7a697e68a2a548d0b08804a8deb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769520600,
      "headline": "Dexcom Schedules Fourth Quarter and Fiscal Year 2025 Earnings Release and Conference Call for February 12, 2026 at 4:30 p.m. Eastern Time.",
      "id": 138270302,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "SAN DIEGO, January 27, 2026--DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2025 financial results after market close on Thursday, February 12, 2026. Management will hold a conference call to review the company's fourth quarter and fiscal year 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations webs",
      "url": "https://finnhub.io/api/news?id=b6963f885beb59a16c2bdc793d1a8d1e59eef7a697e68a2a548d0b08804a8deb"
    }
  },
  {
    "ts": null,
    "headline": "Could 2026 Be Dexcom's 'Get Right' Year? New CEO Jake Leach Says Yes.",
    "summary": "For the first time in a decade, Dexcom has a new chief executive. And, to say Jake Leach has his work cut out for him is underselling it.",
    "url": "https://finnhub.io/api/news?id=5b07033883dbefd6522657798902819d31ac693d6652f47624fb5302b750cef5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769518842,
      "headline": "Could 2026 Be Dexcom's 'Get Right' Year? New CEO Jake Leach Says Yes.",
      "id": 138270303,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "For the first time in a decade, Dexcom has a new chief executive. And, to say Jake Leach has his work cut out for him is underselling it.",
      "url": "https://finnhub.io/api/news?id=5b07033883dbefd6522657798902819d31ac693d6652f47624fb5302b750cef5"
    }
  },
  {
    "ts": null,
    "headline": "2 Mid-Cap Stocks with Exciting Potential and 1 We Ignore",
    "summary": "Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.",
    "url": "https://finnhub.io/api/news?id=00ac44ac210d7e0fb5dc9a2aa822f917de6fcd3528c8f280b96b7c840aa0e421",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769488569,
      "headline": "2 Mid-Cap Stocks with Exciting Potential and 1 We Ignore",
      "id": 138268753,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.",
      "url": "https://finnhub.io/api/news?id=00ac44ac210d7e0fb5dc9a2aa822f917de6fcd3528c8f280b96b7c840aa0e421"
    }
  }
]